| 29171818 |
Fremanezumab for the Preventive Treatment of Chronic Migraine
Goadsby, PJ,
Silberstein, SD,
Blankenbiller, T,
Ma, Y,
Yeung, PP,
Dodick, DW,
Bigal, ME,
Yang, R,
Aycardi, E,
Grozinski-Wolff, M
|
N. Engl. J. Med. |
2017 |
| 32266704 |
Eptinezumab: First Approval
Dhillon, S
|
Drugs |
2020 |
| 26432182 |
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Newman, LC,
Loupe, PS,
Silberstein, SD,
Burstein, R,
Ma, Y,
Lipton, RB,
Rapoport, AM,
Dodick, DW,
Bigal, ME,
Yang, R
|
Lancet Neurol |
2015 |
| 25297013 |
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
Smith, J,
Kudrow, D,
Silberstein, SD,
Ashina, M,
Lipton, RB,
Kohrman, B,
Kroll, R,
Goadsby, PJ,
Wilks, K,
ALD403 study investigators, -,
Dodick, DW,
Olesen, J,
Bargar, R,
Hirman, J
|
Lancet Neurol |
2014 |
| 29255900 |
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial
Goadsby, PJ,
Schacht, A,
Dodick, DW,
Camporeale, A,
Oakes, TM,
Zhang, Q,
Carter, J,
Ferguson, MB,
Johnson, KW,
Shan, Q,
Martinez, J,
Skljarevski, V
|
JAMA Neurol |
2018 |
| 32145209 |
Medications Approved for Preventing Migraine Headaches
Ryan, M,
Spindler, BL
|
Am. J. Med. |
2020 |
